Lomecel-B is a cell therapy commercialized by Longeveron, with a leading Phase II program in Ageing. According to Globaldata, it is involved in 13 clinical trials, of which 7 were completed, 3 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Lomecel-B’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Lomecel-B is expected to reach an annual total of $11 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lomecel-B Overview

Lomecel-B is under development for the treatment of ageing frailty, hypoplastic left heart syndrome in infants, unspecified influenza virus infections and Alzheimer's disease. It is administered through intramyocardial and intravenous route. The drug candidate comprises of allogeneic human mesenchymal stem cells (hMSC).

It was under development for the treatment of acute respiratory distress syndrome caused by coronavirus disease 2019 (COVID-19).

Longeveron Overview

Longeveron is a biotechnology company. It discovers and develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product LOMECEL-B, a cell-based therapy against aging-related chronic diseases. It is also conducting clinical research in the following indications/conditions: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Longeveron works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company operates through manufacturing plants in Miami, Florida, the US. Longeveron is headquartered in West Palm Beach, California, the US.

The company reported revenues of (US Dollars) US$1.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 76.8% over FY2020. The operating loss of the company was US$17.2 million in FY2021, compared to an operating loss of US$3.8 million in FY2020. The net loss of the company was US$17.1 million in FY2021, compared to a net loss of US$3.7 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 43.1% over the previous quarter.

For a complete picture of Lomecel-B’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.